Valneva SE (VALN) Current Assets (2020 - 2026)
Valneva SE (VALN) posted quarterly Current Assets of $229.2 million for Q1 2026, down 29.82% year-on-year from $326.6 million in Q1 2025, and down 9.48% on a QoQ basis from $253.2 million in Q4 2025.
Valneva SE (VALN) Current Assets (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Current Assets for 7 consecutive years, with $229.2 million the latest figure, recorded in Q1 2026.
- Quarterly Current Assets fell 29.82% year-over-year to $229.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229.2 million (down 29.82% YoY) and the FY2025 annual result came in at $253.2 million, down 25.57% from the prior year.
- Current Assets eased to $229.2 million in Q1 2026 per VALN's latest filing, from $253.2 million in the prior quarter.
- Over the last five years, Current Assets for VALN reached as high as $620.2 million in Q1 2022 and fell as low as $229.2 million in Q1 2026.
- A 5-year average of $382.0 million and a median of $345.5 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets plunged 38.11% — and 2024, when it climbed 13.77%.
- Year by year, Current Assets stood at $483.2 million in 2022, then tumbled by 38.11% to $299.1 million in 2023, then grew by 13.77% to $340.3 million in 2024, then decreased by 25.57% to $253.2 million in 2025, then dropped by 9.48% to $229.2 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $229.2 million, $253.2 million, and $305.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 289.93 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 73.04 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 6.60 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 35.73 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 11.73 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 18.21 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 521.86 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 8.07 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.97 Bn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 229.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 229.23 Mn |
| Dec 31, 2025 | 253.24 Mn |
| Sep 30, 2025 | 305.35 Mn |
| Jun 30, 2025 | 323.99 Mn |
| Mar 31, 2025 | 326.65 Mn |
| Dec 31, 2024 | 340.26 Mn |
| Sep 30, 2024 | 345.50 Mn |
| Jun 30, 2024 | 306.28 Mn |
| Mar 31, 2024 | 348.49 Mn |
| Dec 31, 2023 | 299.08 Mn |
| Sep 30, 2023 | 364.89 Mn |
| Jun 30, 2023 | 388.59 Mn |
| Mar 31, 2023 | 443.04 Mn |
| Dec 31, 2022 | 483.24 Mn |
| Sep 30, 2022 | 542.28 Mn |
| Jun 30, 2022 | 573.27 Mn |
| Mar 31, 2022 | 620.21 Mn |
| Dec 31, 2021 | 666.65 Mn |
| Dec 31, 2020 | 350.98 Mn |